New Filings At The EMA
New medicines under evaluation at the European Medicines Agency.
You may also be interested in...
The European Medicines Agency has agreed to review pan-EU marketing applications for a number of new medicines.
The past few months have seen the European Medicines Agency award its much sought-after priority medicines designation to treatments for Hunter syndrome, bubble boy disease and narcolepsy.
Ryzneuta, Evive Biotech’s treatment for chemotherapy-induced neutropenia in cancer patients, is among the latest new medicines that have been submitted for review for potential pan-EU approval.